Skip to main content

Table 3 Effect of cisplatin (CP) and different treatments of AHE on Phase I antioxidant enzymes

From: Modulatory influence of Acacia hydaspica R. Parker ethyl acetate extract against cisplatin inveigled hepatic injury and dyslipidemia in rats

Group POD (U/min) SOD (U/mg protein) CAT (U/min) QR (nM/min/mg protein)
Control 13.40 ± 0.23b 1.55 ± 0.06b 24.02 ± 0.08 b 104.8 ± 1.01b
CP 7.23 ± 0.39a 0.39 ± 0.03a 12.80 ± 0.05 a 67.8 ± 0.88 a
AHE alone 13.09 ± 0.27b 1.55 ± 0.08b 24.03 ± 0.03 b 104.7 ± 1.07 b
CP + AHE 9.21 ± 0.29ab*,d 1.08 ± 0.05a, b 14.70 ± 0.06 a, b, d 82.2 ± 0.89 a, b,d
AHE + CP 12.50 ± 0.66b, c** 1.30 ± 0.03a*, b 20.37 ± 0.08 a, b, c 95.3 ± 0.65 a, b, c
CP + Sily 12.57 ± 0.44b 1.31 ± 0.04a*, b 20.66 ± 0.04 ab 95.9 ± 1.26 a,b
  1. Values expressed as mean ± SEM
  2. a Significance at p < 0.0001 Vs. control group
  3. b Significance at p < 0.0001 Vs. Cisplatin (CP) group
  4. c Significance at p < 0.0001 of AHE + CP pre-treated group Vs. CP + AHE post-treated group
  5. d Significance at p < 0.0001 of CP + AHE treatment groups Vs CP + Sily group
  6. *,** Significant difference at p < 0.001. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters (One way ANOVA followed by Tukey’s multiple comparison tests)